ArticleInternational urology and nephrology2026

A comparison of efficacy and prognosis between RC48 combined immunotherapy and gemcitabine-cisplatin combined immunotherapy in bladder-preserving multimodal therapy for muscle-invasive bladder cancer.

Biao Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.